Evidence map›Paper›PMID 37399106›Full record

ArticleACS nano2023

A Comparative Study of Ultrasmall Calcium Carbonate Nanoparticles for Targeting and Imaging Atherosclerotic Plaque.

Lydia Martínez-Parra, Marina Piñol-Cancer, Carlos Sanchez-Cano, Ana B Miguel-Coello, Desirè Di Silvio, Ana M Gomez, Clara Uriel, Sandra Plaza-García, Marta Gallego, Raquel Pazos and 12 more

Abstract read
In one paragraph

Article in ACS nano, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Lydia Martínez-ParraCenter for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia, Spain.
Marina Piñol-CancerCenter for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia, Spain.
Carlos Sanchez-CanoDonostia International Physics Center, Paseo Manuel de Lardizabal 4, Donostia, 20018, Spain.ORCID 0000-0002-9522-0019
Ana B Miguel-CoelloCenter for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia, Spain.
Desirè Di SilvioCenter for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia, Spain.
Ana M GomezInstituto de Química Orgánica General, IQOG-CSIC, 28006 Madrid, Spain.ORCID 0000-0002-8703-3360
Clara UrielInstituto de Química Orgánica General, IQOG-CSIC, 28006 Madrid, Spain.
Sandra Plaza-GarcíaCenter for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia, Spain.
Marta GallegoCenter for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia, Spain.
Raquel PazosCenter for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia, Spain.
Hugo GroultBiotechnologies et Chimie des Bioressources pour la Santé, Littoral Environment et Sociétés (LIENSs Laboratory), UMR CNRS 7266, 17000 La Rochelle, France.ORCID 0000-0002-1571-9400
Marc JeanninLaboratoire des Sciences de l'Ingénieur pour l'Environnement (LaSIE), UMR-CNRS 7536, La Rochelle Université, 7356 La Rochelle, France.
Kalotina GerakiDiamond Light Source, Harwell Science and Innovation Campus, Didcot OX11 0DE, United Kingdom.
Laura Fernández-MéndezCenter for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia, Spain.
Ainhize Urkola-ArsuagaCenter for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia, Spain.
María Jesús Sánchez-GuisadoCenter for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia, Spain.
Juliana Carrillo-RomeroCenter for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia, Spain.
Wolfgang J ParakCenter for Hybrid Nanostructures (CHyN), Universität Hamburg, 22607 Hamburg, Germany.ORCID 0000-0003-1672-6650
Maurizio PratoCenter for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia, Spain.
Fernando HerranzNanoMedMol, Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), Madrid 28006, Spain.ORCID 0000-0002-3743-0050
Jesús Ruiz-CabelloCenter for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia, Spain.ORCID 0000-0001-8681-5056
Susana Carregal-RomeroCenter for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia, Spain.ORCID 0000-0003-1444-6268

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atherosclerosis is a complex disease that can lead to life-threatening events, such as myocardial infarction and ischemic stroke. Despite the severity of this disease, diagnosing plaque vulnerability remains challenging due to the lack of effective diagnostic tools. Conventional diagnostic protocols lack specificity and fail to predict the type of atherosclerotic lesion and the risk of plaque rupture. To address this issue, technologies are emerging, such as noninvasive medical imaging of atherosclerotic plaque with customized nanotechnological solutions. Modulating the biological interactions and contrast of nanoparticles in various imaging techniques, including magnetic resonance imaging, is possible through the careful design of their physicochemical properties. However, few examples of comparative studies between nanoparticles targeting different hallmarks of atherosclerosis exist to provide information about the plaque development stage. Our work demonstrates that Gd (III)-doped amorphous calcium carbonate nanoparticles are an effective tool for these comparative studies due to their high magnetic resonance contrast and physicochemical properties. In an animal model of atherosclerosis, we compare the imaging performance of three types of nanoparticles: bare amorphous calcium carbonate and those functionalized with the ligands alendronate (for microcalcification targeting) and trimannose (for inflammation targeting). Our study provides useful insights into ligand-mediated targeted imaging of atherosclerosis through a combination of

Indexed as

AtherosclerosisNanoparticlesPlaque, AtheroscleroticAnimalsMagnetic Resonance Imagingamorphous calcium carbonate nanoparticlesatherosclerosisligand-mediated targeted imagingmagnetic resonance imagingsynchrotron X-ray fluorescence tissue analysis

Identifiers

PMID37399106
PMCPMC10900527

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.